Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a hold rating to a buy rating in a research report report published on Saturday morning, Zacks.com reports. The firm currently has $4.50 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. “
Several other research analysts also recently weighed in on LXRX. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, December 25th. Wedbush reiterated a buy rating and set a $17.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Sunday, December 22nd. ValuEngine upgraded shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, January 3rd. Citigroup downgraded shares of Lexicon Pharmaceuticals from a buy rating to a neutral rating and increased their price objective for the company from $3.00 to $4.00 in a research note on Friday, November 8th. Finally, Gabelli downgraded shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, December 11th. They noted that the move was a valuation call. Eight equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $6.50.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.80. The business had revenue of $294.45 million during the quarter, compared to the consensus estimate of $12.00 million. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The business’s quarterly revenue was up 4124.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.26) earnings per share. Equities research analysts predict that Lexicon Pharmaceuticals will post 1.01 EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of LXRX. Point72 Asset Management L.P. bought a new position in Lexicon Pharmaceuticals during the 3rd quarter valued at $1,590,000. Vanguard Group Inc. boosted its stake in Lexicon Pharmaceuticals by 8.1% during the 2nd quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock valued at $26,670,000 after acquiring an additional 319,382 shares during the last quarter. Wedbush Securities Inc. boosted its stake in Lexicon Pharmaceuticals by 105.1% during the 3rd quarter. Wedbush Securities Inc. now owns 398,684 shares of the biopharmaceutical company’s stock valued at $1,200,000 after acquiring an additional 204,345 shares during the last quarter. First Manhattan Co. raised its holdings in shares of Lexicon Pharmaceuticals by 7.3% during the second quarter. First Manhattan Co. now owns 2,949,979 shares of the biopharmaceutical company’s stock worth $18,555,000 after purchasing an additional 201,393 shares during the period. Finally, Morgan Stanley raised its holdings in shares of Lexicon Pharmaceuticals by 158.0% during the second quarter. Morgan Stanley now owns 195,307 shares of the biopharmaceutical company’s stock worth $1,229,000 after purchasing an additional 119,611 shares during the period. Hedge funds and other institutional investors own 96.24% of the company’s stock.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Story: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.